Literature DB >> 24899301

Hepatitis C: Treatment triumphs.

Charles M Rice1, Mohsan Saeed1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24899301     DOI： 10.1038/510043a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  15 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Daclatasvir plus sofosbuvir for HCV infection.

Authors:  Mark S Sulkowski; Ira M Jacobson; David R Nelson
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

Review 3.  25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

Authors:  Markus H Heim
Journal:  Nat Rev Immunol       Date:  2013-06-07       Impact factor: 53.106

4.  Clinical and serological analysis of transfusion-associated hepatitis.

Authors:  H J Alter; P V Holland; A G Morrow; R H Purcell; S M Feinstone; Y Moritsugu
Journal:  Lancet       Date:  1975-11-01       Impact factor: 79.321

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

8.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

9.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
View more
  11 in total

1.  The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.

Authors:  David P Durham; Laura A Skrip; Robert Douglas Bruce; Silvia Vilarinho; Elamin H Elbasha; Alison P Galvani; Jeffrey P Townsend
Journal:  Clin Infect Dis       Date:  2015-11-30       Impact factor: 9.079

2.  Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).

Authors:  Marion Mora; Trevor Goodyear; Fabienne Marcellin; Jeannie Shoveller; Vincent Di Beo; Chiara Calzolaio; Philippe Sogni; Linda Wittkop; David Zucman; Isabelle Poizot-Martin; Karine Lacombe; Dominique Salmon-Céron; Rod Knight; Patrizia Carrieri
Journal:  J Viral Hepat       Date:  2020-09-24       Impact factor: 3.728

3.  Synergistic Activity of Combined NS5A Inhibitors.

Authors:  Donald R O'Boyle; Peter T Nower; Min Gao; Robert Fridell; Chunfu Wang; Piyasena Hewawasam; Omar Lopez; Yong Tu; Nicholas A Meanwell; Makonen Belema; Susan B Roberts; Mark Cockett; Jin-Hua Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral Replication.

Authors:  Ascensión Ariza-Mateos; Rosa Díaz-Toledano; Timothy M Block; Samuel Prieto-Vega; Alex Birk; Jordi Gómez
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

Review 5.  PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis.

Authors:  Aline Awad; Ama Gassama-Diagne
Journal:  World J Hepatol       Date:  2017-01-08

6.  NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus.

Authors:  Shafi Kuchay; Mohsan Saeed; Carlotta Giorgi; Jie Li; Hans-Heinrich Hoffmann; Paolo Pinton; Charles M Rice; Michele Pagano
Journal:  Cell Rep       Date:  2018-10-23       Impact factor: 9.423

7.  NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.

Authors:  Luiza M Bessa; Hélène Launay; Marie Dujardin; François-Xavier Cantrelle; Guy Lippens; Isabelle Landrieu; Robert Schneider; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.486

8.  Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions.

Authors:  Luciana Santos Pessoa; Luãnna Liebscher Vidal; Emmerson C B da Costa; Celina Monteiro Abreu; Rodrigo Delvecchio da Cunha; Ana Luiza Chaves Valadão; André Felipe Dos Santos; Amilcar Tanuri
Journal:  Genet Mol Biol       Date:  2016 Jul-Sep       Impact factor: 1.771

9.  Epidemiology of Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis.

Authors:  Daniel J Smith; Josh Neurer; Ashly E Jordan; Holly Hagan
Journal:  JMIR Res Protoc       Date:  2017-10-20

Review 10.  Hepatitis C Vaccines, Antibodies, and T Cells.

Authors:  Naglaa H Shoukry
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.